---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-005903"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2024-08-19T23:59:59+00:00"
generated_at: "2026-05-31T08:39:17.152112+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma Q2 revenue $9.3M (+67% YoY); net loss narrows 45% to $(494K)

## Summary
- Q2 gross revenue $9,303,067, up 67% from $5,560,865 in Q2 2023.
- Net loss for Q2 2024 was $(494,300) vs $(902,108) in Q2 2023, a 45% improvement.
- YTD revenue $16,844,113, up 61% from $10,454,918; YTD net loss $(1,778,101) improved 32%.
- Sequential Q2 sales grew 23% over Q1 2024 sales of $7,541,046.
- Shareholders' equity $23,489,865, up 11% from Dec 31, 2023.

## SEC filing metadata
- accession: 0001683168-24-005903
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2024-08-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316824005903/0001683168-24-005903-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316824005903/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-005903
- JSON: https://secwatch.observer/filing/0001683168-24-005903.json
- Plain text: https://secwatch.observer/filing/0001683168-24-005903.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.